BARD1 Life Sciences (ASX:BD1) receives positive results from breast cancer study

In Clinical Studies News by Barbara Jacoby

Spread the love

By: Julia Seymour

From: themarketherald.com

  • BARD1 Life Sciences (BD1) has received results from a preliminary study demonstrating the feasibility of using SubB2M in an immunohistochemistry (IHC) application for breast cancer tissue
  • The study compared cancer tissue from an invasive ductual breast cancer tumour biopsy to a non-cancer breast tissue biopsy
  • The study also demonstrated that the SubB2M IHC test could be performed on automated staining equipment regularly used in pathology laboratories worldwide.
  • Once the staining has been optimised for breast cancer tissue, the company says it plans to extend its studies to other cancer applications
  • BARD1 Life Sciences is up 1.65 per cent, trading at $2.46

BARD1 Life Sciences (BD1) has received results from a preliminary study demonstrating the feasibility of using SubB2M in an immunohistochemistry (IHC) application for breast cancer tissue.

SubB2M is a protein that binds specifically to a sugar, Neu5Gc, that is associated with a range of cancers — a sugar normal human cells and tissues do not typically express. This is the first time the protein has been used to demonstrate staining of cancer in specific tissue sections.

The study compared cancer tissue from an invasive ductual breast cancer tumour biopsy to a non-cancer breast tissue biopsy.

The study also demonstrated that the SubB2M IHC test could be performed on automated staining equipment regularly used in pathology laboratories worldwide.

“Whilst this data is from a single patient sample, and the assay conditions have not been optimised, we are pleased that we were able to utilise SubB2M to achieve a positive staining outcome in breast cancer FFPE sections,” said BARD1 CSO Dr Peter French.

BARD1 CEO Dr Leearne Hinch says this represents a potential product opportunity for BARD1’s expanding cancer diagnostic pipeline.

“The global immunohistochemical market was valued at U.S.$1.8 billion in 2019 and SubB2M-based IHCs could be developed for cancers such as melanoma where it can be difficult to distinguish malignant from benign tissues,” said Dr Hinch.

Once the staining has been optimised for breast cancer tissue, BARD1 says it plans to extend its studies to other cancer applications.